Himalaya Therapeutics Announces Highlights of Recent Clinical Progress
Himalaya Therapeutics Announces Highlights of Recent Clinical Progress By Himalaya Therapeutics | News | November 8, 2022 Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolled HTBA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in Phase 2 part 2 of study anticipated to begin by year-end CAB-CTLA-4 […]
Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)
Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011) By Himalaya Therapeutics | News | September 12, 2022 Preliminary observations in Non-Small Cell Lung Cancer (“NSCLC”) support advancing to the registrational stage of the trial; anticipate full interim data set in 4Q’22 Undifferentiated Pleomorphic Sarcoma (“UPS”) and osteosarcoma will advance to Phase 2, part […]
Himalaya Therapeutics Announces Submission In Mainland China Of IND Applications For Its CAB-AXL-ADC To Treat Sarcomas And NSCLC, Its CAB-ROR2-ADC To Treat Melanoma And NSCLC
HIMALAYA THERAPEUTICS ANNOUNCES SUBMISSION IN MAINLAND CHINA OF IND APPLICATIONS FOR ITS CAB-AXL-ADC TO TREAT SARCOMAS AND NSCLC, ITS CAB-ROR2-ADC TO TREAT MELANOMA AND NSCLC By Himalaya Therapeutics | News | October 4, 2021 SHANGHAI and SAN DIEGO, Oct. 4, 2021 /PRNewswire/ – Himalaya Therapeutics (“Himalaya”), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China, of a novel class of investigational […]
Himalaya Therapeutics Announces Registration Of Its Office In Shanghai
HIMALAYA THERAPEUTICS ANNOUNCES REGISTRATION OF ITS OFFICE IN SHANGHAI By Himalaya Therapeutics | News | August 23, 2021 简 SHANGHAI and SAN DIEGO, Aug. 23, 2021 /PRNewswire/ – Himalaya Therapeutics (“Himalaya”), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China, of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the […]
Himalaya Therapeutics Announces Appointment Of Howe Li As Chief Medical Officer
HIMALAYA THERAPEUTICS ANNOUNCES APPOINTMENT OF HOWE LI AS CHIEF MEDICAL OFFICER By Himalaya Therapeutics | News | August 23, 2021 简 SAN DIEGO, May 3, 2021 /PRNewswire/ – Himalaya Therapeutics (“Himalaya”), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on […]
Himalaya Therapeutics Announces Appointment Of Brian Zhang As Chief Executive Officer
HIMALAYA THERAPEUTICS ANNOUNCES APPOINTMENT OF BRIAN ZHANG AS CHIEF EXECUTIVE OFFICER By Himalaya Therapeutics | News | August 23, 2021 简 SAN DIEGO, April 26, 2021 /PRNewswire/ – Himalaya Therapeutics (“Himalaya”), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the […]
Himalaya Therapeutics Announces Appointment Of Nicholas Desjardins As Chief Financial Officer
HIMALAYA THERAPEUTICS ANNOUNCES APPOINTMENT OF NICHOLAS DESJARDINS AS CHIEF FINANCIAL OFFICER By Himalaya Therapeutics | News | August 23, 2021 简 April 12, 2021: SAN DIEGO, CA and HONG KONG, CHINA – Himalaya Therapeutics (“Himalaya”), a clinical-stage oncology-focused biopharmaceutical company focused on development and commercialization in Greater China, and globally, of a novel class of investigational antibody […]
Generating Tumor-Selective Conditionally Active Biologic Anti-CTLA4 Antibodies Via Protein-Associated Chemical Switches
GENERATING TUMOR-SELECTIVE CONDITIONALLY ACTIVE BIOLOGIC ANTI-CTLA4 ANTIBODIES VIA PROTEIN-ASSOCIATED CHEMICAL SWITCHES By Himalaya Therapeutics | News | January 19, 2021 Recent publication by our co-founder and chairman, Jay Short, that discussing the mechanism he developed that enables our product candidates to be conditionally active around cancer cells. View PDF View LinkedIn post Share on facebook Share […]